Abstract 5257: FGF9 overexpression promotes tumorigenic potential of non-small cell lung cancer (NSCLC) cells, and is associated with poor prognosis in NSCLC patients.
Kota Ishioka(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Keiko Ohgino(Keio University), Satoshi Yoda(Harvard University), Aoi Kuroda(Keio University), Daisuke Arai(Keio University), Katsuhiko Naoki(Broad Institute), Takashi Sato(Kitasato University), Hiroyuki Yasuda(Keio University), Kenzo Soejima(Keio University), Junko Hamamoto(Keio University), Tetsuo Tani(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
|Clinical Cancer Research|2021|137